Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

2ITW

Crystal structure of EGFR kinase domain in complex with AFN941

Summary for 2ITW
Entry DOI10.2210/pdb2itw/pdb
Related1DNQ 1DNR 1IVO 1M14 1M17 1MOX 1NQL 1XKK 1YY9 1Z9I 2ITN 2ITO 2ITP 2ITQ 2ITT 2ITU 2ITV 2ITX 2ITY 2ITZ
DescriptorEPIDERMAL GROWTH FACTOR RECEPTOR, 1,2,3,4-Tetrahydrogen Staurosporine (3 entities in total)
Functional Keywordsreceptor, cell cycle, atp-binding, transferase, transmembrane, phosphorylation, disease mutation, polymorphism, glycoprotein, anti-oncogene, nucleotide-binding, alternative splicing, afn941, egfr, kinase, staurosporine, membrane, tyrosine-protein kinase, epidermal growth factor
Biological sourceHOMO SAPIENS (HUMAN)
Cellular locationCell membrane; Single-pass type I membrane protein. Isoform 2: Secreted: P00533
Total number of polymer chains1
Total formula weight37772.68
Authors
Yun, C.-H.,Boggon, T.J.,Li, Y.,Woo, S.,Greulich, H.,Meyerson, M.,Eck, M.J. (deposition date: 2006-05-25, release date: 2007-04-03, Last modification date: 2023-12-13)
Primary citationYun, C.-H.,Boggon, T.J.,Li, Y.,Woo, S.,Greulich, H.,Meyerson, M.,Eck, M.J.
Structures of Lung Cancer-Derived Egfr Mutants and Inhibitor Complexes: Mechanism of Activation and Insights Into Differential Inhibitor Sensitivity
Cancer Cell, 11:217-, 2007
Cited by
PubMed Abstract: Mutations in the EGFR kinase are a cause of non-small-cell lung cancer. To understand their mechanism of activation and effects on drug binding, we studied the kinetics of the L858R and G719S mutants and determined their crystal structures with inhibitors including gefitinib, AEE788, and a staurosporine. We find that the mutations activate the kinase by disrupting autoinhibitory interactions, and that they accelerate catalysis as much as 50-fold in vitro. Structures of inhibitors in complex with both wild-type and mutant kinases reveal similar binding modes for gefitinib and AEE788, but a marked rotation of the staurosporine in the G719S mutant. Strikingly, direct binding measurements show that gefitinib binds 20-fold more tightly to the L858R mutant than to the wild-type enzyme.
PubMed: 17349580
DOI: 10.1016/J.CCR.2006.12.017
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.88 Å)
Structure validation

227111

數據於2024-11-06公開中

PDB statisticsPDBj update infoContact PDBjnumon